-
- R Alexanian
- University of Texas M.D. Anderson Cancer Center, Houston 77030.
-
- MA Dimopoulos
- University of Texas M.D. Anderson Cancer Center, Houston 77030.
-
- K Delasalle
- University of Texas M.D. Anderson Cancer Center, Houston 77030.
-
- B Barlogie
- University of Texas M.D. Anderson Cancer Center, Houston 77030.
書誌事項
- 公開日
- 1992-08-15
- DOI
-
- 10.1182/blood.v80.4.887.bloodjournal804887
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:p>Intermittent courses of dexamethasone (DEX) were administered to 112 consecutive, previously untreated patients with multiple myeloma (MM). Using criteria based on a 75% or greater reduction of calculated tumor mass, the overall response rate was 43%. Among comparable patients, response rate were approximately 15% less than those observed previously with vincristine-doxorubicin by continuous infusion with intermittent DEX (VAD) and similar to those with melphalan-prednisone. The projected survival times with VAD or DEX were similar. Results indicated that DEX accounted for most of the plasma cell reduction achieved with VAD. Serious complications occurred in 27% of patients treated with VAD, but in only 4% of those who received DEX. In view of the similar outcome with fewer serious complications, DEX provided a simple, effective, and safe primary treatment for a large fraction of patients with MM. Patients who appear most likely to benefit include those with hypercalcemia or pancytopenia, or who require simultaneous radiotherapy for a pathologic fracture.</jats:p>
収録刊行物
-
- Blood
-
Blood 80 (4), 887-890, 1992-08-15
American Society of Hematology